Cebranopadol

Human clinical Neuroprotection 3 sources

Cebranopadol is a novel, first-in-class analgesic that acts as a dual agonist at both the nociceptin/orphanin FQ peptide (NOP) receptor and the µ-opioid receptor (MOP). Research shows it provides potent pain relief across various pain models, including neuropathic and nociceptive pain, with a potentially improved safety profile compared to traditional opioids.

01Dosing reference

Amount

200-600 mcg/day (clinical trial dosing)

Frequency

Once daily

Cycle

Continuous daily use for chronic pain management

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

NOP and MOP receptor agonism

Cebranopadol binds to and activates both the nociceptin/orphanin FQ peptide (NOP) receptor and the µ-opioid receptor (MOP).

Synergistic pain modulation

Activation of MOP provides strong analgesia, while NOP activation modulates the opioid response, enhancing pain relief and mitigating some typical opioid side effects.

Broad-spectrum analgesia

This dual mechanism offers potential for treating severe acute and chronic pain, including neuropathic pain, with a wider therapeutic window.

03Human evidence

Efficacy in chronic lower back pain and osteoarthritis

Phase II and III clinical trials have demonstrated significant pain reduction in patients with chronic lower back pain and osteoarthritis, comparable to or better than traditional opioids.

Efficacy in diabetic polyneuropathy

Clinical studies have shown it is effective in reducing pain scores in patients with painful diabetic polyneuropathy, a condition often resistant to standard treatments.

04Preclinical evidence

Potent analgesia in diverse pain models

Animal models of acute, inflammatory, and neuropathic pain showed broad-spectrum analgesic efficacy, often with higher potency than morphine.

Reduced respiratory depression and abuse potential

Rodent studies indicated a wider safety margin for respiratory depression and lower rewarding properties compared to selective MOP agonists, attributed to the NOP receptor component.

05What is known vs. unknown

Reasonably established

Acts as a dual agonist at NOP and MOP receptors.
Demonstrates broad-spectrum analgesic efficacy in both nociceptin and neuropathic pain.
Shows a potentially wider therapeutic window compared to traditional opioids.
Has been evaluated in multiple Phase II and III clinical trials for chronic pain conditions.

Unknowns & limits

Long-term safety and efficacy in diverse patient populations remain to be fully established.
The exact clinical abuse liability compared to newer abuse-deterrent opioids requires further real-world data.
Optimal dosing strategies for transitioning from other strong analgesics are still being refined.

06Safety & regulatory context

Regulatory statusCebranopadol is an investigational drug and is not yet FDA-approved for general use. In clinical trials, it has shown a side effect profile typical of opioids, including dizziness, nausea, vomiting, and constipation, though potentially with a lower incidence of severe respiratory depression. Because it acts on the µ-opioid receptor, it carries inherent risks of dependence and abuse, although preclinical data suggests this may be attenuated by its NOP activity. It is subject to strict regulatory oversight and would likely be scheduled as a controlled substance if approved.

07Compared with Buprenorphine

Cebranopadol vs. Buprenorphine

Key difference

While buprenorphine is a partial MOP agonist and KOP antagonist, cebranopadol is a full agonist at both MOP and NOP receptors.

When researchers discuss each

Buprenorphine is often discussed in the context of opioid use disorder and moderate pain, whereas cebranopadol is researched as a novel approach for severe, difficult-to-treat chronic and neuropathic pain where traditional opioids fail or cause intolerable side effects.

08Glossary

Nociceptin/orphanin FQ peptide (NOP) receptor

A receptor in the central nervous system involved in pain regulation, reward, and anxiety.

µ-opioid receptor (MOP)

The primary receptor targeted by traditional opioid painkillers, responsible for analgesia but also respiratory depression and addiction.

Agonist

A substance that binds to a receptor and activates it to produce a biological response.

Neuropathic pain

Pain caused by damage or disease affecting the somatosensory nervous system, often described as burning or shooting.

09Knowledge check

Q1What is the primary mechanism of action of cebranopadol?

Q2What potential advantage does cebranopadol's NOP receptor activity provide over traditional opioids?

Q3Which limitation in the current clinical evidence for cebranopadol is explicitly noted in the dossier and would most directly affect generalizing trial results to a wider range of patients?

Q4When researchers discuss cebranopadol compared with buprenorphine, which statement best captures the pharmacological distinction given in the dossier?

Q5Which regulatory or safety statement about cebranopadol is supported by the dossier?

10Sources

More in Neuroprotection

See all

Cerebrolysin

Neuroprotection

Human clinical

Cerebrolysin is a complex mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue. Research indicates it mimics the action of endogenous neurotrophic factors, promoting neuroprotection, neurogenesis, and synaptic plasticity. It has been extensively studied and utilized in clinical settings for stroke recovery, traumatic brain injury, and neurodegenerative conditions like Alzheimer's disease.

5-50 mL per day depending on the severity of the condition (e.g., 5 mL IM for mild cognitive issues, up to 50 mL IV for acute stroke)

Pinealon

Neuroprotection

Early human

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) designed to act as a peptide bioregulator for the brain and central nervous system. Research suggests it interacts directly with DNA to regulate gene expression, offering neuroprotective effects, improving cognitive function, and reducing oxidative stress in brain cells.

1-2 mg per day (SubQ) or 10-20 mg per day (Oral)

ARA-290 (Cibinetide)

Neuroprotection

Human clinical

ARA-290, also known as Cibinetide, is an engineered peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating red blood cell production. Research has primarily focused on its potential to reduce inflammation, promote tissue repair, and alleviate neuropathic pain, particularly in conditions like sarcoidosis and diabetic neuropathy.

4 mg/day

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.